3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Recurrence
1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Neoplasms
1
Lymphoproliferative Disorders
1
Immunoproliferative Disorders
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Amyloidosis
1
Interventions
tisagenlecleucel
2
fludarabine
2
blinatumomab
2
Cyclophosphamide
2
zanubrutinib
1
selinexor
1
revumenib
1
niraparib
1
nilotinib
1
ivosidenib
1
imetelstat
1
ibrutinib
1
entrectinib
1
dostarlimab
1
brexucabtagene autoleucel
1
avapritinib
1
asciminib
1
Standard of Care
1
Paclitaxel
1
Imatinib Mesylate
1
GRN163L peptide
1
Drug Therapy
1
Dexamethasone
1
Dasatinib
1
Carboplatin
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Recurrence
×
Dexamethasone
×
Clear all
NCT03110562
2024-08-21
BOSTON
Karyopharm Therapeutics Inc
Phase 3
Completed
402 enrolled
22 charts
1 FDA